ArticleFrontiers in medicine2020
Cytomegalovirus: A Troll in the ICU? Overview of the Literature and Perspectives for the Future.
Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Does treatment with antiviral medication affect mortality among immunocompetent individuals with cytomegalovirus reactivation? A systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Viral Reactivation in Immunocompetent Critically Ill Patients.Microorganisms · 2026Review
- Clinical Characteristics and Outcomes of Cytomegalovirus DNAemia in Non-HIV-Infected and Non-Transplant Patients: A Propensity Score-Matched Analysis.Pathogens (Basel, Switzerland) · 2026Article
- Time-series clustering analysis reveals distinct patterns of cytomegalovirus viremia in critically ill adults.Intensive care medicine experimental · 2026Article
- Bilateral Vocal Cord Paralysis Following Influenza A: Case Report.Clinical case reports · 2026Article
- Risk stratification for CMV reactivation in sepsis patients: development of an interpretable machine learning model.BMC infectious diseases · 2025Article
- Cytomegalovirus reactivation in the lower respiratory tract as an independent risk factor for mortality in critically Ill patients.Critical care (London, England) · 2025Article
- Viral reactivations and fungal infections in nonresolving acute respiratory distress syndrome.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Cytomegalovirus infection in non-immunocompromised critically ill patients: A management perspective.World journal of virology · 2024Review
- Diagnosis of Human Cytomegalovirus Drug Resistance Mutations in Solid Organ Transplant Recipients-A Review.Diagnostics (Basel, Switzerland) · 2024Review
- Diagnostic stewardship to limit repeat plasma cytomegalovirus viral load testing.BMC infectious diseases · 2023Article
- Review
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses.Microorganisms · 2023Review
- Lipopolysaccharide Tolerance Enhances Murine Norovirus Reactivation: An Impact of Macrophages Mainly Evaluated by Proteomic Analysis.International journal of molecular sciences · 2023Article
- Review
- Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection.Open forum infectious diseases · 2022Article
- The role of polyspecific T-cell exhaustion in severe outcomes for COVID-19 patients having latent pathogen infections such as Toxoplasmagondii.Microbial pathogenesis · 2021Article
- A role for T-cell exhaustion in Long COVID-19 and severe outcomes for several categories of COVID-19 patients.Journal of neuroscience research · 2021Review
- SARS-CoV-2 and Cytomegalovirus Co-Infections-A Case Series of Critically Ill Patients.Journal of clinical medicine · 2021Article
- EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) is one of the most pathogenic viruses in human. After a primary infection, CMV resides in the host for life as a latent infection. When immunity is reduced, CMV can escape the suppressive effects of the immune system and lead to viremia and antigenemia. This reactivation, first seen in transplant patients, has also been documented in non-immunocompromised CMV-seropositive critically ill patients and is associated with higher morbidity and mortality. In the latter, it is not clear whether CMV reactivation is an innocent bystander or the cause of this observed worse outcome. Two studies showed no difference in the outcome of CMV-seropositive and seronegative patients. In addition, proof-of-concept studies investigating prophylactic antiviral treatment to prevent CMV reactivation during critical illness, failed to show a beneficial effect on interleukin levels or clinical outcome. Further research is necessary to resolve the question whether CMV replication impairs the prognosis in non-immunocompromised critically ill patients. We here give a concise overview on the available data and propose strategies to further unravel this question. First, post-mortem investigation may be useful to evaluate the effect of viral replication on organ inflammation and function. Second, further research should focus on the question whether the level of viremia needs to exceed a threshold to be associated with worse outcome. Third, clinical and biochemical assessments may help to identify patients at high risk for reactivation. Fourth, preemptive treatment based upon early detection of the virus is currently under investigation. Finally, immune-stimulating biologicals may be beneficial in high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.